Following the success of EGFR TKIs, the discovery of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene in 2007 elicited a significant change in the therapeutic strategies for NSCLC patients harboring the specific aberrant gene [6]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.